Thyronorm Oral Solution for Cats

Država: Avstralija

Jezik: angleščina

Source: APVMA (Australian Pesticides and Veterinary Medicines Authority)

Aktivna sestavina:

THIAMAZOLE

Dostopno od:

NORBROOK LABORATORIES AUSTRALIA PTY LIMITED

Farmacevtska oblika:

ORAL SOLUTION/SUSPENSION

Sestava:

THIAMAZOLE UNGROUPED Active 5.0 mg/ml

Enote v paketu:

100 mL; 30 mL

Razred:

VM - Veterinary Medicine

Terapevtsko območje:

ENDOCRINE SYSTEM

Povzetek izdelek:

Poison schedule: 4; Withholding period: ; Host/pest details: CAT: [HYPERTHYROIDISM]

Status dovoljenje:

Registered

Datum dovoljenje:

2023-07-01

Navodilo za uporabo

THYRONORM ORAL SOLUTION FOR CATS
91237/131482
Product Name:
APVMA Approval No:
Label Name:
THYRONORM ORAL SOLUTION FOR CATS
Signal Headings:
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
READ SAFETY DIRECTIONS BEFORE OPENING OR USING
Constituent
Statements:
5 mg/mL Thiamazole
Claims:
Label Claim (i.e. carton or cardboard front panel label and container
label claim)
For the stabilisation of hyperthyroidism in cats prior to surgical
thyroidectomy.
For the long term treatment of feline hyperthyroidism.
Leaflet Claim
INDICATIONS
Thyronorm Oral Solution for Cats is indicated for both the
stabilisation of hyperthyroidism
in cats prior to surgical thyroidectomy and for the long term
treatment of feline
hyperthyroidism.
Net Contents:
30 mL
100 mL
Directions for Use:
Restraints:
Contraindications:
Do not use in cats suffering from concurrent systemic diseases such as
severe primary liver
disease or diabetes mellitus.
Do not use in cats showing signs of autoimmune disease such as
anaemia, multiple
inflamed joints, skin ulceration and crusting.
Do not use in animals with disorders of white blood cells, such as
neutropaenia and
lymphopaenia. Symptoms may include lethargy and increased
susceptibility to infection. RLP APPROVED
Do not use in animals with platelet disorders and coagulopathies
(particularly
thrombocytopenia). Symptoms may include bruising and excessive
bleeding from wounds.
Do not use in pregnant or lactating females.
Do not use in case of hypersensitivity to the active substance or to
any of the excipients.
Precautions:
Concurrent treatment with phenobarbital may reduce the clinical
efficacy of thiamazole.
Thiamazole is known to reduce the hepatic oxidation of benzimidazole
wormers and may
lead to increases in their plasma concentrations when given
concurrently. Thiamazole
is immunomodulatory, therefore this should be taken into account when
considering
vaccination programmes.
Do not administer in food as efficacy of the product when administered
via this route has
not been